Company intelligence / Profile preview

MAPS Europe

Ownership: Private
Development stage: Phase 3

Overview

MAP Europe is a leading consultancy specializing in market access for biopharma, biotech, medtech, and digital health companies. They provide strategic support to help clients achieve optimal results in pricing, reimbursement, and health technology assessments across European markets. Their expertise includes early engagement with payers and stakeholders to accelerate patient access to innovative treatments.

Industry: Consulting

Drug pipeline

1 asset

mdma

Phase 3

Indications: Post-traumatic stress disorder (PTSD)

Beyond the preview

Go deeper on MAPS Europe.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAPS Europe.

Explore the full profile